中文版 | English

在结果中检索

HFCAS OpenIR

浏览/检索结果: 共2条，第1-2条 帮助

限定条件    
已选(0)清除 条数/页：   排序方式：
Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial 期刊论文
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 卷号: 18
作者:  Li, Ning;  Zhu, Jianqing;  Yin, Rutie;  Wang, Jing;  Pan, Lingya;  Kong, Beihua;  Zheng, Hong;  Liu, Jihong;  Wu, Xiaohua;  Wang, Li;  Huang, Yi;  Wang, Ke;  Zou, Dongling;  Zhao, Hongqin;  Wang, Chunyan;  Lu, Weiguo;  Lin, An;  Lou, Ge;  Li, Guiling;  Qu, Pengpeng;  Yang, Hongying;  Zhen, Xiaoa;  Hang, Wenzhao;  Hou, Jianmei;  Banerjee, Ashish;  Wu, Lingying
收藏  |  浏览/下载：40/0  |  提交时间：2022/12/23
Olaparib maintenance monotherapy in Chinese patients with platinum-sensitive relapsed ovarian cancer: China cohort from the phase III SOLO2 trial 期刊论文
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022
作者:  Liu, Jihong;  Yin, Rutie;  Wu, Lingying;  Zhu, Jianqing;  Lou, Ge;  Wu, Xiaohua;  Zhou, Qi;  Gao, Yunong;  Kong, Beihua;  Lu, Xin;  Wang, Jing;  Chen, Youguo;  Cheng, Ying;  Wang, Yueling;  Lu, Weiguo;  Li, Wei;  Ma, Xin;  Hsu, Kate
收藏  |  浏览/下载：57/0  |  提交时间：2022/05/05
BRCA mutation  China  olaparib  ovarian cancer  PARP inhibitor